Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26

Kairos Pharma, LTD.

Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.
Trading begins November 26, 2024 at 10:00 a.m. ET under ticker 'KAPA'.
Dual listing aims to access global investor base outside U.S., unlock liquidity, enhance price discovery.
CEO John Yu says listing supports shareholder value and advancement of lead drug ENV105 in cancer trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.